{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:15:44Z","timestamp":1790910944428,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Fundamental Research Funds for the Central Universities","award":["3332020055"],"award-info":[{"award-number":["3332020055"]}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81421002 and 81730006"],"award-info":[{"award-number":["81421002 and 81730006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81920108006 and 81630007"],"award-info":[{"award-number":["81920108006 and 81630007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81570181 and 81400174"],"award-info":[{"award-number":["81570181 and 81400174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences","award":["CAMS 2017-I2M-1-015 and CAMS-2016-I2M-3-031"],"award-info":[{"award-number":["CAMS 2017-I2M-1-015 and CAMS-2016-I2M-3-031"]}]},{"name":"Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences","award":["CAMS-2017-I2M-1-005"],"award-info":[{"award-number":["CAMS-2017-I2M-1-005"]}]},{"name":"Tianjin Science and Technology Supporting Program","award":["17JCYBJC27900"],"award-info":[{"award-number":["17JCYBJC27900"]}]},{"name":"the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2018RC320012"],"award-info":[{"award-number":["2018RC320012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anaemia is the most common complication of myeloma and is associated with worse clinical outcomes. Although marrow replacement with myeloma cells is widely considered a mechanistic rationale for anaemia, the exact process has not been fully understood. Our large cohort of 1363 myeloma patients had more than 50% of patients with moderate or severe anaemia at the time of diagnosis. Anaemia positively correlated with myeloma cell infiltration in the bone marrow (BM) and worse patient outcomes. The quantity and erythroid differentiation of HSPCs were affected by myeloma cell infiltration in the BM. The master regulators of erythropoiesis, GATA1 and KLF1, were obviously downregulated in myeloma HSPCs. However, the gene encoding the chemokine CCL3 showed significantly upregulated expression. Elevated CCL3 in the BM plasma of myeloma further inhibited the erythropoiesis of HSPCs via activation of CCL3\/CCR1\/p38 signalling and suppressed GATA1 expression. Treatment with a CCR1 antagonist effectively recovered GATA1 expression and rescued erythropoiesis in HSPCs. Myeloma cell infiltration causes elevated expression of CCL3 in BM, which suppresses the erythropoiesis of HSPCs and results in anaemia by downregulating the level of GATA1 in HSPCs. Thus, our study indicates that targeting CCL3 would be a potential strategy against anaemia and improve the survival of myeloma patients.<\/jats:p>","DOI":"10.1038\/s41598-020-77450-y","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T06:03:44Z","timestamp":1606284224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment"],"prefix":"10.1038","volume":"10","author":[{"given":"Lanting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoke","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"77450_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"9","key":"77450_CR2","first-page":"806","volume":"17","author":"Y Kawano","year":"2017","unstructured":"Kawano, Y., Roccaro, A. M., Ghobrial, I. M. & Azzi, J. Multiple myeloma and the immune microenvironment. Curr. Cancer Drug Targets 17(9), 806\u2013818 (2017).","journal-title":"Curr. Cancer Drug Targets"},{"issue":"6","key":"77450_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.clml.2013.06.001","volume":"13","author":"C Konig","year":"2013","unstructured":"Konig, C. et al. Prevalence of iron overload vs iron deficiency in multiple myeloma: resembling or different from MDS\u2013and stem cell transplant (SCT)\u2013patients?. Clin. Lymphoma Myeloma Leuk. 13(6), 671\u2013680 (2013).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"9","key":"77450_CR4","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI200420945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth, E. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig. 113(9), 1271\u20131276 (2004).","journal-title":"J. Clin. Investig."},{"issue":"23","key":"77450_CR5","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1182\/blood-2010-05-286260","volume":"116","author":"LT Goodnough","year":"2010","unstructured":"Goodnough, L. T., Nemeth, E. & Ganz, T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116(23), 4754\u20134761 (2010).","journal-title":"Blood"},{"issue":"4","key":"77450_CR6","first-page":"233","volume":"2","author":"H Ludwig","year":"2004","unstructured":"Ludwig, H., Pohl, G. & Osterborg, A. Anemia in multiple myeloma. Clin. Adv. Hematol. Oncol. 2(4), 233\u2013241 (2004).","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"7483","key":"77450_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12984","volume":"505","author":"SJ Morrison","year":"2014","unstructured":"Morrison, S. J. & Scadden, D. T. The bone marrow niche for haematopoietic stem cells. Nature 505(7483), 327\u2013334 (2014).","journal-title":"Nature"},{"issue":"22","key":"77450_CR8","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood-2015-07-533588","volume":"126","author":"LM Calvi","year":"2015","unstructured":"Calvi, L. M. & Link, D. C. The hematopoietic stem cell niche in homeostasis and disease. Blood 126(22), 2443\u20132451 (2015).","journal-title":"Blood"},{"issue":"1","key":"77450_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano, Y. et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 263(1), 160\u2013172 (2015).","journal-title":"Immunol. Rev."},{"issue":"9","key":"77450_CR10","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3109\/10428194.2011.576791","volume":"52","author":"M Hao","year":"2011","unstructured":"Hao, M. et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leukemia Lymphoma 52(9), 1787\u20131794 (2011).","journal-title":"Leukemia Lymphoma"},{"key":"77450_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1756-8722-4-37","volume":"4","author":"M Hao","year":"2011","unstructured":"Hao, M. et al. Suppressing miRNA-15a\/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J. Hematol. Oncol. 4, 37 (2011).","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"77450_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00018-016-2306-y","volume":"74","author":"A Sanchez-Aguilera","year":"2017","unstructured":"Sanchez-Aguilera, A. & Mendez-Ferrer, S. The hematopoietic stem-cell niche in health and leukemia. Cell. Mol. Life Sci. CMLS 74(4), 579\u2013590 (2017).","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"77450_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fphys.2014.00003","volume":"5","author":"J Palis","year":"2014","unstructured":"Palis, J. Primitive and definitive erythropoiesis in mammals. Front. Physiol. 5, 3 (2014).","journal-title":"Front. Physiol."},{"issue":"8","key":"77450_CR14","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1182\/blood-2013-02-482919","volume":"122","author":"Y Yang","year":"2013","unstructured":"Yang, Y. et al. RARalpha2 expression confers myeloma stem cell features. Blood 122(8), 1437\u20131447 (2013).","journal-title":"Blood"},{"issue":"11","key":"77450_CR15","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","volume":"97","author":"JH Han","year":"2001","unstructured":"Han, J. H. et al. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 97(11), 3349\u20133353 (2001).","journal-title":"Blood"},{"issue":"7","key":"77450_CR16","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/leu.2011.43","volume":"25","author":"S Vallet","year":"2011","unstructured":"Vallet, S. et al. A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 25(7), 1174\u20131181 (2011).","journal-title":"Leukemia"},{"issue":"1","key":"77450_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M. & Dimopoulos, M. A. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 8(1), 7 (2018).","journal-title":"Blood Cancer J."},{"issue":"1","key":"77450_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 70(1), 7\u201330 (2020).","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl 1","key":"77450_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hon.2586","volume":"37","author":"SV Rajkumar","year":"2019","unstructured":"Rajkumar, S. V. Multiple myeloma: every year a new standard?. Hematol. Oncol. 37(Suppl 1), 62\u201365 (2019).","journal-title":"Hematol. Oncol."},{"issue":"7","key":"77450_CR20","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1172\/JCI31370","volume":"117","author":"C Peyssonnaux","year":"2007","unstructured":"Peyssonnaux, C. et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Investig. 117(7), 1926\u20131932 (2007).","journal-title":"J. Clin. Investig."},{"issue":"2","key":"77450_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7861\/clinmedicine.13-2-193","volume":"13","author":"J Cullis","year":"2013","unstructured":"Cullis, J. Anaemia of chronic disease. Clin. Med. 13(2), 193\u2013196 (2013).","journal-title":"Clin. Med."},{"issue":"7193","key":"77450_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature07038","volume":"453","author":"LI Zon","year":"2008","unstructured":"Zon, L. I. Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. Nature 453(7193), 306\u2013313 (2008).","journal-title":"Nature"},{"issue":"11","key":"77450_CR23","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood-2015-01-623645","volume":"126","author":"H Cheng","year":"2015","unstructured":"Cheng, H. et al. Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. Blood 126(11), 1302\u20131313 (2015).","journal-title":"Blood"},{"issue":"13","key":"77450_CR24","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2011-04-347484","volume":"120","author":"I Bruns","year":"2012","unstructured":"Bruns, I. et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood 120(13), 2620\u20132630 (2012).","journal-title":"Blood"},{"issue":"6","key":"77450_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3324\/haematol.2014.118000","volume":"100","author":"J Bordini","year":"2015","unstructured":"Bordini, J. et al. Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma. Haematologica 100(6), 834\u2013841 (2015).","journal-title":"Haematologica"},{"issue":"3","key":"77450_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/MOH.0000000000000333","volume":"24","author":"L Tumburu","year":"2017","unstructured":"Tumburu, L. & Thein, S. L. Genetic control of erythropoiesis. Curr. Opin. Hematol. 24(3), 173\u2013182 (2017).","journal-title":"Curr. Opin. Hematol."},{"issue":"11","key":"77450_CR27","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1016\/j.celrep.2019.05.046","volume":"27","author":"LS Ludwig","year":"2019","unstructured":"Ludwig, L. S. et al. Transcriptional states and chromatin accessibility underlying human erythropoiesis. Cell Rep. 27(11), 3228\u20133240 (2019).","journal-title":"Cell Rep."},{"issue":"1","key":"77450_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tig.2013.10.001","volume":"30","author":"PE Love","year":"2014","unstructured":"Love, P. E., Warzecha, C. & Li, L. Ldb1 complexes: the new master regulators of erythroid gene transcription. Trends Genet. TIG 30(1), 1\u20139 (2014).","journal-title":"Trends Genet. TIG"},{"issue":"5","key":"77450_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41580-019-0103-9","volume":"20","author":"S Pinho","year":"2019","unstructured":"Pinho, S. & Frenette, P. S. Haematopoietic stem cell activity and interactions with the niche. Nat. Rev. Mol. Cell Biol. 20(5), 303\u2013320 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"77450_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1517\/13543784.2013.738666","volume":"22","author":"SZ Fields","year":"2013","unstructured":"Fields, S. Z. et al. Activin receptor antagonists for cancer-related anemia and bone disease. Exp. Opin. Investig. Drugs 22(1), 87\u2013101 (2013).","journal-title":"Exp. Opin. Investig. Drugs"},{"key":"77450_CR31","doi-asserted-by":"publisher","first-page":"30998","DOI":"10.1038\/srep30998","volume":"6","author":"N Deshet-Unger","year":"2016","unstructured":"Deshet-Unger, N. et al. Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss. Sci. Rep. 6, 30998 (2016).","journal-title":"Sci. Rep."},{"issue":"5","key":"77450_CR32","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1096\/fj.14-259085","volume":"29","author":"S Hiram-Bab","year":"2015","unstructured":"Hiram-Bab, S. et al. Erythropoietin directly stimulates osteoclast precursors and induces bone loss. FASEB J. 29(5), 1890\u20131900 (2015).","journal-title":"FASEB J."},{"issue":"2","key":"77450_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/leu.2015.259","volume":"30","author":"BD Palma","year":"2016","unstructured":"Palma, B. D. et al. Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20. Leukemia 30(2), 409\u2013416 (2016).","journal-title":"Leukemia"},{"issue":"2","key":"77450_CR34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/jid.2012.333","volume":"133","author":"L Chen","year":"2013","unstructured":"Chen, L., Wu, J., Pier, E., Zhao, Y. & Shen, Z. mTORC2-PKBalpha\/Akt1 serine 473 phosphorylation axis is essential for regulation of FOXP3 Stability by chemokine CCL3 in psoriasis. J. Invest. Dermatol. 133(2), 418\u2013428 (2013).","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"77450_CR35","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","volume":"101","author":"S Lentzsch","year":"2003","unstructured":"Lentzsch, S. et al. Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101(9), 3568\u20133573 (2003).","journal-title":"Blood"},{"issue":"9","key":"77450_CR36","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/leu.2016.81","volume":"30","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1alpha\/CCL3. Leukemia 30(9), 1897\u20131908 (2016).","journal-title":"Leukemia"},{"issue":"4","key":"77450_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","volume":"15","author":"IM Ghobrial","year":"2018","unstructured":"Ghobrial, I. M., Detappe, A., Anderson, K. C. & Steensma, D. P. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat. Rev. Clin. Oncol. 15(4), 219\u2013233 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"77450_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1034\/j.1600-0609.2003.00009.x","volume":"70","author":"CP McGuckin","year":"2003","unstructured":"McGuckin, C. P., Forraz, N. & Liu, W. M. Diaminofluorene stain detects erythroid differentiation in immature haemopoietic cells treated with EPO, IL-3, SCF, TGFbeta1, MIP-1alpha and IFNgamma. Eur. J. Haematol. 70(2), 106\u2013114 (2003).","journal-title":"Eur. J. Haematol."},{"issue":"5\u20136","key":"77450_CR39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10585-006-9038-6","volume":"23","author":"E Menu","year":"2006","unstructured":"Menu, E. et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin. Exp. Metas. 23(5\u20136), 291\u2013300 (2006).","journal-title":"Clin. Exp. Metas."},{"issue":"7","key":"77450_CR40","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1182\/blood-2011-10-384784","volume":"120","author":"DJ Dairaghi","year":"2012","unstructured":"Dairaghi, D. J. et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 120(7), 1449\u20131457 (2012).","journal-title":"Blood"},{"issue":"10","key":"77450_CR41","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1359\/jbmr.2002.17.10.1785","volume":"17","author":"C Higuchi","year":"2002","unstructured":"Higuchi, C. et al. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 17(10), 1785\u20131794 (2002).","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"14","key":"77450_CR42","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1038\/sj.emboj.7601228","volume":"25","author":"A Hernandez-Hernandez","year":"2006","unstructured":"Hernandez-Hernandez, A. et al. Acetylation and MAPK phosphorylation cooperate to regulate the degradation of active GATA-1. EMBO J. 25(14), 3264\u20133274 (2006).","journal-title":"EMBO J."},{"issue":"7086","key":"77450_CR43","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nature04651","volume":"440","author":"F Castellino","year":"2006","unstructured":"Castellino, F. et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440(7086), 890\u2013895 (2006).","journal-title":"Nature"},{"issue":"1","key":"77450_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2010.02.009","volume":"295","author":"Q Cao","year":"2010","unstructured":"Cao, Q. et al. Therapeutic effect of MIP-1alpha-recruited dendritic cells on preestablished solid and metastatic tumors. Cancer Lett. 295(1), 17\u201326 (2010).","journal-title":"Cancer Lett."},{"issue":"26","key":"77450_CR45","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J. Clin. Oncol. 33(26), 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."},{"key":"77450_CR46","unstructured":"WHO: Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity (Geneva, World Health Organization 2011) (WHO\/NMH\/NHD\/MNM\/11.1)"},{"issue":"1","key":"77450_CR47","doi-asserted-by":"publisher","first-page":"15030","DOI":"10.1038\/s41598-018-33396-w","volume":"8","author":"K Maes","year":"2018","unstructured":"Maes, K. et al. The genetic landscape of 5T models for multiple myeloma. Sci. Rep. 8(1), 15030 (2018).","journal-title":"Sci. Rep."},{"issue":"3","key":"77450_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41389-020-0216-1","volume":"9","author":"M Zang","year":"2020","unstructured":"Zang, M. et al. Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s. Oncogenesis 9(3), 31 (2020).","journal-title":"Oncogenesis"},{"key":"77450_CR49","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/1541-7786.MCR-19-0852","volume":"18","author":"T Yu","year":"2020","unstructured":"Yu, T. et al. Polycomb-like protein 3 induces proliferation and drug resistance in multiple myeloma and is regulated by miRNA-15a. Mol. Cancer Res. 18, 1063\u20131073 (2020).","journal-title":"Mol. Cancer Res."},{"key":"77450_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-020-0161-3","author":"Z Li","year":"2020","unstructured":"Li, Z. et al Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma. Cancer Gene Ther. https:\/\/doi.org\/10.1038\/s41417-020-0161-3 (2020).","journal-title":"Cancer Gene Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77450-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77450-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77450-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T18:47:50Z","timestamp":1670352470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77450-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["77450"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-77450-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"assertion":[{"value":"12 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20508"}}